Clinical trials: Hepatobiliary Disorders
Type 2 Diabetes Mellitus With Complication
Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease
Type 2 diabetes mellitus (T2DM) is always accompanied with nonalcoholic fatty liver disease (NAFLD).This prospective, randomized controlled intervention study was designed to reveal the potential clinical application and…
- Trial name
- NCT05422092
- Testing
- Canagliflozin, Pioglitazone
- Volunteers
- 80 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Normobaric Hypoxia
Effects of Normobaric Hypoxic Training in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Altitude training has been suggested to be of potential support to improve some chronic clinical conditions, especially metabolic conditions.
- Trial name
- HYPOMASLD (NCT07073326)
- Testing
- HYPOTRAIN, NORMOTRAIN
- Where
- Italy
- Volunteers
- 16 people
- Sponsor
- University of Trieste
Liver Cancer, Hepatitis B
Viral & Host Factors Associated With Hepatitis B Virus-related Hepatocellular Carcinoma
Adult liver cancer is the third leading cause of cancer deaths worldwide. The major risk factor for liver cancer is hepatitis B virus (HBV) infection.
- Conditions
- Liver Cancer, Hepatitis B, Hepatitis C, Hepatobiliary Cancers Liver
- Trial name
- NCT00767936
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- Stanford University
Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Study of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohepatitis
Primary purpose: Compare the changes in liver triglycerides concentration in the Aramchol versus the placebo arm following three month treatment.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Metabolic Syndrome
- Trial name
- Aramchol003 (NCT01094158)
- Testing
- Aramchol
- Where
- 11 sites in Israel
- Volunteers
- 60 people
- Sponsor
- Galmed Medical Reserch
Obesity, Exercise
Structured Exercise Prescription Program in Obese Children
This controlled clinical trial aims to compare the effects of a multicomponent program that includes structured personalized exercise prescription in children with obesity with a control group that will be enrolled in a…
- Conditions
- Obesity, Exercise, Cardiovascular Risk Factor, Liver Diseases
- Trial name
- NCT03552367
- Testing
- Personalized structured exercise program, Non personalized non-structured exercise program
- Where
- Mexico
- Volunteers
- 140 people
- Sponsor
- Hospital General de México Dr. Eduardo Liceaga
NAFLD, MASH
Prospective Cohort and Biobank of Patients With Nonalcoholic Fatty Liver Disease
The goal of this observational study is to establish a unified cohort for retrospective and prospective high quality baseline and follow-up data registration of patients with a diagnosis of NAFLD/NASH/MAFLD, according to…
- Conditions
- NAFLD, MASH, NASH/MASH
- Trial name
- NAFLD Cohort (NCT07051863)
- Where
- Switzerland
- Volunteers
- 300 people
- Sponsor
- Fondazione Epatocentro Ticino
Diabetes Mellitus, Type 2, NAFLD
Screening of Liver Fibrosis Using Blood Tests in Patients With Type 2 Diabetes Mellitus
Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic SteatoHepatitis (NASH), are a frequent complication of type 2 diabetes and obesity.
- Conditions
- Diabetes Mellitus, Type 2, NAFLD, NASH
- Trial name
- L-FibroT2DM (NCT04232293)
- Testing
- Blood tests
- Where
- 2 sites in France
- Volunteers
- 722 people
- Sponsor
- Nantes University Hospital
Metabolic Dysfunction-Associated Steatotic Liver Disease
Effects of Different Exercises on Intrahepatic Lipid in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease
This is a single-center, randomized, parallel controlled study to explore the effects of aerobic exercise, resistance exercise or aerobic combined resistance exercise on liver lipid in patients with MASLD, consisting of a 12-week…
- Trial name
- NCT06994871
- Testing
- Aerobic exercise, Resistance exercise, combined exercise
- Where
- 2 sites in China
- Volunteers
- 186 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Obesity, NASH - Nonalcoholic Steatohepatitis
Diagnostic Accuracy of the "LLIFT", a Novel Non-invasive Biomarker for the Diagnosis of Non Alcoholic Fatty Liver (NAFL) and SteatoHepatitis (NASH) in a Population With High Risk of Metabolic Syndrome"
The NAFLD is the first cause of liver disease worldwide. The severe form of NAFLD, the NASH progresses to cirrhosis and is responsible of liver mortality.
- Trial name
- LLIFT (NCT04616664)
- Where
- 7 sites in France
- Volunteers
- 158 people
- Sponsor
- University Hospital, Lille
Non-alcoholic Fatty Liver Disease
Prospective Cohort Assessing the Role of the Genotoxin Colibactin From Escherichia Coli B2 in the Genesis of NASH
In a population of patients with Non Alcoholic Fatty Liver Disease (NAFLD), the investigators will compare the composition of the gut microbiota from patients with simple steatosis with that with steatohepatitis.
- Trial name
- Coli-NASH (NCT02390232)
- Testing
- liver biopsy, collection of stools, blood sample
- Where
- France
- Volunteers
- 176 people
- Sponsor
- University Hospital, Toulouse
Hepatocellular Carcinoma (HCC)
A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma
This investigational study will evaluate if using a combination of TACE along with high dose SBRT would show improvement in local control in patients with Hepatocellular Carcinoma.
- Trial name
- RAD 0902 (NCT01247298)
- Testing
- Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Alabama at Birmingham
Metabolic Dysfunction-Associated Steatotic Liver Disease
The Impact of Nutrition Education and Rice Bran Supplementation on Metabolic Dysfunction-associated Steatotic Liver Disease
This study aims to evaluate the effects of nutrition education with or without rice bran supplementation in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
- Trial name
- NCT07524621
- Testing
- Nutrition Education, Rice Bran
- Where
- Taiwan
- Volunteers
- 58 people
- Sponsor
- Shih Chien University
Non-Alcoholic Fatty Liver Disease
Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLD
This clinical trial aims to investigate the effects of TOTUM-448, a mix of 5 plant extracts and choline, consumed at the daily regimen of two times per day, on liver fat content, cardiometabolic risk factors and gut microbiota…
- Trial name
- CARDIO-LIVER (NCT06704321)
- Testing
- TOTUM-448
- Where
- Canada
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Valbiotis
Non-Alcoholic Fatty Liver Disease
Ultrasound Quantification of Liver Fat
The investigators plan a prospective study designed to evaluate the accuracy of a new ultrasound method for quantification of liver fat content.
- Trial name
- NCT04523584
- Testing
- Magnetic Resonance Imaging (MRI), Ultrasound Imaging
- Where
- United States
- Volunteers
- 192 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Nonalcoholic Steatohepatitis
Phase I Pharmacokinetic Study of HUYPS-1 in Healthy Volunteers
Fasting Period: At least 10 hours prior to dosing until 4 hours post-dose of each study period. Period: 24 hours post dose in each period. Each subject will complete two study periods.
- Trial name
- NCT05983328
- Testing
- HUYPS-1 one tablet, HUYPS-1 nine tablets
- Where
- Taiwan
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Sinew Pharma Inc.
Cirrhosis, Portal Hypertension
A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis
Endothelin is a human hormone which has been associated with increased portal pressure in patients with liver cirrhosis (also called portal hypertension). Ambrisentan blocks the effects of endothelin.
- Conditions
- Cirrhosis, Portal Hypertension, Ascites
- Trial name
- NCT03827200
- Testing
- Ambrisentan
- Where
- 6 sites in Spain
- Volunteers
- 19 people
- Sponsor
- Noorik Biopharmaceuticals AG
Alpha-1 Antitrypsin Deficiency (AATD)
A Study of TSRA-196 in Adults With PiZZ Alpha-1 Antitrypsin Deficiency (AATD)
This is a Phase 1/2, open-label, multi-center, dose escalation (Part 1), dose expansion (Part 2), and single repeat dose (Part 3) study to evaluate the safety, tolerability, efficacy, and PK/PD parameters of TSRA-196 in adults…
- Trial name
- NCT07227207
- Testing
- TSRA-196
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 72 people
- Sponsor
- Tessera Therapeutics, Inc.
NAFLD, NASH - Nonalcoholic Steatohepatitis
Vitamin E for NASH Treatment in HIV Infected Individuals
The purpose of this study is to see how taking Vitamin E daily affects fatty liver in persons living with HIV. Subjects will have both HIV and a fatty liver and the purpose of the study is to learn if underlying liver condition…
- Conditions
- NAFLD, NASH - Nonalcoholic Steatohepatitis, HIV Infections
- Trial name
- NCT03669133
- Testing
- Vitamin E
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Indiana University
Alcoholic Cirrhosis, Alcohol Abstinence
Safety & Efficacy of Baclofen for Alcohol Withdrawal in Chronic Liver Disease With Active Alcohol Consumption
This study examines the safety and effectiveness of baclofen as a treatment for alcohol withdrawal in patients with chronic liver disease who continue drinking.
- Conditions
- Alcoholic Cirrhosis, Alcohol Abstinence, Alcohol Withdrawal, Medication Toxicity
- Trial name
- BAWIC (NCT06840652)
- Testing
- Baclofen
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- Corporacion Parc Tauli
Liver Fibrosis Progression in Chronic Liver Disease
LIVER FIBROSIS PREVALENCE IN FRANCE
"Mortality related to complications of cirrhosis, (hemorrhage, hepatic insufficiency and primary liver cancer) is 15,000 per year in France.
- Trial name
- FIBROFRANCE (NCT01927133)
- Where
- France
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.